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Introduction
Acne vulgaris is a common chronic skin disease, predominant in adolescence but also affecting a large number of adults [1, 2, 3] . Although acne is not associated directly with mortality or conventionally defined morbidity, the discomfort, risk of scarring and often strong emotional distress associated with the condition means it is increasingly considered a valid target for treatment rather than a condition to be endured [4, 5] . Acne is defined by the presence of inflamed red papules, pustules, comedones (black or whiteheads) and the pathogenesis of the condition involves a complex sequence of events, including sebum production, hyperkeratinisation, poral occlusion, colonisation by Propionibacterium acnes (P. acnes) bacteria and a persistent inflammatory immune response [6] . Microcomedones are often the initial subclinical acne lesions which further mature into non-inflammatory comedones and/or inflammatory lesions [7, 8] . The development of microcomedone is via hyperkeratinisation (keratin/infundibular plug) in the follicular infundibulum and sebaceous ducts [8] . Follicular epithelial hyperproliferation leads to hyperkeratosis and eventually to the formation of microcomedones and this may be promoted by increased sebum production. Hyperkeratosis is characterised by increased number and size of keratohyaline granules, lipid droplet accumulation, and epidermal scale/keratin flakes [9] . Consequent alteration in lipid composition of sebum, bacterial overgrowth, and hormonal factors elicit stimulation of the immune and inflammatory responses via the action of CD3 + , CD4
+ (lymphocytes) and macrophages [6, 8, 9] . The local overproduction of androgen hormones including testosterone, dehydroepiandrosterone sulfate, and dihydrotestosterone can regulate sebaceous gland growth and sebum production and consequently the formation of acne lesions [7, 9, 10, 11] .
Furthermore, androgen is involved in comedogenesis and hyperkeratinisation via regulating growth factors and IL-1α [8] . Insulin-like growth factor-1 production, stimulated by growth hormone, acts on sebaceous glands by causing their growth and stimulating lipogenesis [7, 8, 9] . Under certain circumstances, P. acnes, a common commensal Gram-positive anaerobic bacterium (usually a benign inhabitant of sebaceous follicles) may act directly or indirectly on pilosebaceous ducts and activate certain inflammatory proteins (including the pro-inflammatory cytokines) [12] causing inflammation and hyperkeratinisation [8] . However, it has also been reported that comedones can develop in the absence of P. acnes [13] .
A range of conventional treatments for acne exist including oral and topical retinoids, antibiotics, benzoyl peroxide and hormonal treatments [14] , but concerns over side effects of retinoids including severe depression [15] and the development of antibiotic resistance to P. acnes [16] have created an appetite for novel treatments, including the use of herbal preparations [17, 18] .
Eladi Keram is a commercially available Ayurvedic herbal formulation with a long standing anecdotal evidence base as an effective treatment for various skin conditions including acne (referred in classical Ayurvedic text as "pidaka" a form of Kushta (skin disease)) [19, 20] . 
Materials and methods

Study design and study groups
A randomised controlled pilot study was conducted to evaluate the effectiveness of Eladi Keram for participants with acne on their shoulders and backs in a double-blinded clinical observation. Eladi Keram was selected for the study because it met our selection criteria of being a commercially available traditional medicine with long-standing use, and with claims of efficacy by traditional medicine practitioners and users. The study deliberately focused on subjects with acne on the shoulders and backs rather than on the face.
Although greater emotional distress is associated with facial acne [3] and therefore its targeting may be more beneficial, this is countered by the greater likelihood of participants self-treating and/or masking facial acne during the trial.
This would lead to the increased possibility of introducing confounding variables in such subjects suggesting that a study on back and shoulder acne would in practice be more scientifically robust. Moreover, any potential benefits noted in the treatment of back and shoulder acne are also likely to be relevant to subjects with facial acne.
There is a higher prevalence of acne in 15 -24 year olds but some older people have been confirmed as sufferers as evidenced by UK GP returns analysis [21] .
In this study, under 18 year olds were excluded from the study due to ethical and recruitment issues. participants were required to demonstrate a statistically significant and clinically meaningful reduction in acne. From 24 enquiries, three recruits did not fulfil the inclusion criteria. A total of 21 participants (6 male and 15 female) therefore were enrolled. Ten were randomly (using Minitab ® statistical software random data sampling function (Minitab Ltd. Coventry, U.K.)) assigned to the treatment group and eleven to the control group.
Ethical approval was granted by Middlesex University Ethics Natural Sciences
Sub-Committee and written informed consent was obtained from each participant prior to study commencement.
Test samples
Eladi Keram was purchased from Nagarjuna Ayurvedic Group (http://www.nagarjunaayurveda.com/) and the constituent herbs were authenticated by the manufacturers using thin layer chromatography fingerprinting according to the Indian Government Good Manufacturing
Practice. Eladi Keram contains 27 dried herbal ingredients (Table 1) collation/analysis, thus triple-blinding the study.
Assessment of the effect of Eladi Keram and coconut oil on acne
Participants attended enrolment consultations where they were assessed and provided written consent prior to being given a patch test and being shown how to apply the topical medication, either the treatment formulation (Eladi Keram) or the vehicle control (coconut oil). Briefly, participants were instructed to place the container in warm water to liquefy the contents prior to shaking the bottle gently and then applying approximately 5 mL to the affected areas once a day.
They were also instructed not to apply any other product during the study.
Clinical assessment was undertaken according to the Investigator's Static
Global Assessment Scale (IGA scale), recommended by the US Food and Drug
Administration [22] . Grades were recorded, alongside lesion counts documenting inflammatory and non-inflammatory lesions as separate categories on an anonymous record sheet coded with participant identifier number. Photographs were taken of each participant's back and shoulders for an ancillary visual record. The IGA scale builds on grading systems originating in the seminal research of Burke and Cunliffe [23] . Using this scale, 0 is the absence of lesions and 4 indicates the most severe condition. Reduction to 1 or 0 can be viewed as a successful treatment, as can a 2-point reduction in severity which was also deemed as a clinically meaningful effect size for sample determination (Section 2.4).
On day 28 day of self-treatment, participants returned for debriefing and assessment. Nineteen of the 21 participants returned for follow up. Five participants elected to continue with treatment and were monitored beyond 28 days. These participants were requested to return on day 56 for assessment.
This allowed longer range data to be collected which are also reported herein.
Statistical Analysis
Statistical analyses were performed using Minitab® statistical software. Sample size was determined using a power calculation on the basis that a 2-point reduction on the IGA scale was considered a clinically meaningful effect size. A conventional approach of a 4:1 ratio of β:α risk was employed and therefore a power value of 0.8 and a significance value of 0.05 together with a conservative a priori assumption of an anticipated standard deviation of 1.5 points in the sample IGA scores were used for the sample size calculation. Using these parameters, a sample size of 10 in each group achieved a power of 0.805.
Significance of shifts within control and treatment groups from day 0 -day 28
(and thence for some subjects to day 56) were analysed using paired two-tailed t tests. Comparisons of these shifts between treatment and control group were conducted using two sample (independent) t tests. Assumptions of homogeneity of variance and underlying normality of distributions were tested using standard equal variance testing and the Anderson-Darling normality test as appropriate.
Ordinal data (IGA scale) was analysed using the Mann-Whitney U test.
Comparisons to other studies (where raw measurements could not be directly compared) were made using Cohen's-d measure.
Results
The effect of Eladi Keram and coconut oil on acne
Summarised results for inflammatory lesion counts, non-inflammatory lesion counts, combined lesion counts and the IGA scale for the control (n=11) and treatment (n=10) groups are presented in Fig. 1 . The 95% confidence intervals for the mean shifts in lesion counts and IGA scale measures in the treatment group strongly suggest significant improvements in this group. In contrast, the lesion count and IGA measures show insufficient evidence of any improvement in the control group, with some measures indicating a small deterioration in skin condition.
The mean changes observed at 28 days were directly compared for the treatment group versus the control group for the three lesion counts using independent two sample t tests. Inflammatory lesion count showed a mean improvement of -8 (p=0.037); non-inflammatory lesion count an improvement of -16 (p=0.011) and the combined lesion count gave an improvement of -24 (p=0.003). IGA changes were subjected to the Mann-Whitney U test which showed a median shift of 1 scale grade unit (p=0.007). These results summarised in Fig. 1 show the significant improvement made in the treatment group compared to the control group across the four assessed parameters.
None of the four effect measures yielded significant results in the control group.
Two participants did not complete the trial and stated that they had abandoned treatment due to a lack of improvement in their condition. Under standard protocol these subjects were recorded as having static results unchanged after treatment. Unblinding revealed both were in the control group, an outcome which was concomitant with the control group results as well as the overall study findings. 
Review of the anti-bacterial and anti-inflammatory effect of constituents of Eladi Keram from the literature
Eladi Keram contains 27 herbs; 15 have been reported to possess antibacterial properties and 22 to have anti-inflammatory properties. Eleven herbs are reputed to possess both antibacterial and anti-inflammatory properties.
Discussion
Eladi Several factors, including bacterial infection by P. acnes contribute to the development of acne. However, P. acnes is no longer believed to be the cause of acne and the role of this bacterium in the pathogenesis of acne is still unclear [12] . Fifteen of the constituent herbs of Eladi Keram have been reported to exert an antibacterial effect against different strains of bacteria (Table 1) . However, there are only two reports on the inhibitory action of herbs in Eladi Keram against P. acnes namely Cinnamomum zeylanicum (in the form of an essential oil) [36] and Ipomoea pes-tigridis (compounds in the methanolic extract) [49] .
Although the anti-bacterial action of Eladi Keram against P. acnes specifically has not been demonstrated, other potential modes of action exist including antiinflammatory activity. The process of acne lesion formation is initiated by various immune changes and inflammatory responses [6, 8] . Twenty-two (out of 27) constituents of Eladi Keram exert anti-inflammatory effects (Table 1) via different mechanisms. For example, Tsai et al. [30] reported that Calophyllum inophyllum significantly inhibits the expression of proinflammatory proteins, including the transcriptional factor, nuclear factor-kappaB (NF-κB), cyclooxygenase-2 and inducible nitric oxide (enzymes involved in the production of prostaglandin E 2 and nitric oxide, respectively). C. zeylanicum is also reported to exert anti-inflammatory effects (both in vivo and in vitro) through the inhibition of tumour necrosis factor-α (TNF-α) [38] . Eladi Keram may therefore inhibit pro-inflammatory proteins, thus reducing inflammation, but this effect has yet to be tested. Another potential pathway is a keratolytic effect on hardened pore openings to reduce poral occlusion. Coconut oil (the base oil for the formula) is known generally as an emollient which helps to prevent the epidermis drying, making the skin better able to retain water [70] . This quality may help to prevent poral occlusion and would apply equally to both the control and treatment groups in this study. This could explain the reason some participants in the control group experienced a reduction in non-inflammatory lesion count after treatment with coconut oil, but given the significant improvement in the treatment group this mechanism clearly cannot wholly which increases in response to skin bacterial presence [6, 9] . Excessive sebum production provides an anaerobic growth setting for P. acnes in part due to its lipid content, and produces lipases which hydrolyse triglycerides into proinflammatory free fatty acids [8] . Macrophages surrounding the pilosebaceous follicles are presented with Toll-like receptors (TLRs), a subtype of pattern recognition receptors [7] . TLR-2 and TLR-4 are specific for acne pathogenesis and they can be stimulated by P. acnes ligation [8] . Activated TLR induces NF-κB thus promoting the transcription of chemokines and adhesion molecules and lead to increased production of the cytokines, IL-1, IL-6, IL-8, IL-10, IL-12, and TNF-α, triggering an inflammatory response in acne patients which presents as visible inflammatory lesions [7, 8, 9] . The sebaceous glands also work as localised independent endocrine organs responding to hormones, as well as being involved in neurological signalling and immune type responses. This has an important role in responding to stress and maintaining normal functioning [6, 9] . This suggests control of sebocytes' function and maintenance of 
Conclusion
This study is the first reported clinical evaluation of Eladi Keram's effectiveness in treating acne. We were able to show a clinically meaningful and statistically significant improvement of upper body Acne vulgaris under randomised and double blinded conditions. Given the relatively small sample size employed, 
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